Please find enclosed the Investor Presentation on the Audited Financial Results for the quarter and financial year ended on March 31, 2026.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Thyrocare Technologies reported strong Q4FY26 results with consolidated revenue of ₹224 crore (+20% YoY) and EBITDA of ₹75 crore (+31% YoY), with EBITDA margin expanding to 34% from 31% in Q4FY25. For full year FY26, revenue grew 21% to ₹829 crore while EBITDA jumped 38% to ₹262 crore with margin improving to 32% from 28% in FY25. PAT more than doubled in Q4 (+128% YoY) and grew 81% for FY26 to ₹163 crore. Operationally, tests conducted increased 23% to 209.6 million, active franchisees reached a record ~10,800 (+15% YoY), and the test menu expanded to 1,275 tests (+39% YoY) with new technologies like Next Gen sequencing and ImmunoCAP. Tanzania operations were fully consolidated as a subsidiary during the year.
The company demonstrated consistent margin expansion and strong profitability growth, indicating operational leverage from its franchise network expansion and test menu diversification. The 25% CAGR in franchisee count since FY21 shows sustainable network growth, while the new brand ambassador (Madhuri Dixit) and national awards strengthen brand positioning.